natgillin/translations-raw huggingface dataset:
However, in field studies 10% of seronegative dogs did not show seroconversion (>0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Međutim, u terenskom ispitivanju 10% seronegativnih pasa nije pokazalo serokonverziju (> 0,1 IJ/ml) 3 - 4 tjedna nakon prvog osnovnog cijepljenja protiv bjesnoće.
However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Međutim, u ljudi uporaba sevoflurana povećava intenzitet i trajanje neuromuskularne blokade inducirane nedepolarizirajućim mišićnim relaksansima.
However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Međutim, u ljudi uporaba sevoflurana povećava kako intenzitet, tako i trajanje neuromuskularne blokade inducirane nedepolarizirajućim mišićnim relaksansima.
However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Međutim, u u ljudi uporaba sevoflurana povećava intenzitet i trajanje neuromuskularne blokade inducirane nedepolarizirajućim mišićnim relaksansima.
However, in individuals who are already infected with one or more of the vaccine HPV types, Silgard can still protect against diseases associated with the other HPV types in the vaccine.
Međutim, pojedince koji su već zaraženi jednim ili više tipova HPV-a sadržanim u cjepivu, Silgard i dalje može zaštititi od bolesti prouzročenih preostalim tipovima HPV-a sadržanih u cjepivu.
However, in keeping with the ALARA (“As Low As Reasonably Achievable”) principle, for minimisation of radiation exposure, it is recommended to minimise the time spent in radiation areas, to maximise the distance to radiation sources, and to use adequate shielding.
Međutim, sukladno načelu ALARA (“As Low As Reasonably Achievable” – što je razumno moguće niže), za smanjenje izlaganja zračenju preporučuje se smanjiti vrijeme koje se provodi u području zračenja, povećati udaljenost od izvora zračenja i koristiti odgovarajuću zaštitnu opremu.
However, in multiple myeloma the rates of overall survival and disease progression (the length of time until the disease gets worse) were worse in patients treated with Xgeva than patients treated with zoledronic acid, and the Committee decided that thebenefits did not outweigh the risks for these patients.
No, u slučaju multipla mjeloma su stope ukupnog preživljenja i progresije bolesti (duljine razdoblja do pogoršanja bolesti) bile lošije u bolesnika liječenih lijekom Xgeva u odnosu na bolesnike liječene zoledronatnom kiselinom, te je Odbor odlučio da u slučaju ovih bolesnika koristi ne nadmašuju rizike.
However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).
Međutim, u jednom od tih ispitivanja – ispitivanju fiksne doze – postojala je značajna povezanost između odgovora na dozu i cerebrovaskularnih nuspojava u bolesnika liječenih aripiprazolom (vidjeti dio 4.8).
However, in one of these trials, a fixed-dose trial, there was a significant dose- response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).
Međutim, u jednom od tih ispitivanja, ispitivanju fiksne doze, postojao je značajan odnos odgovor-doza za cerebrovaskularne nuspojave u bolesnika liječenih aripiprazolom (vidjeti dio 4.8).
However, in patients receiving dabigatran, a clinically relevant interaction cannot be excluded when combined with clarithromycin.
Međutim, u bolesnika koji primaju dabigatran, klinički relevantne interakcije ne mogu biti isključene kada se kombinira s klaritromicinom.
However, in patients with mild to moderate hepatic impairment, the exposures of free concentrations of LBQ657 increased by 1.47- and 3.08-fold, respectively, and the exposures of free concentrations of valsartan increased by 1.09-fold and
Međutim, u bolesnika s blagim do umjerenim oštećenjem jetre izloženosti slobodnih koncentracija LBQ657 povećale su se za 1,47 odnosno
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but < 60 ml/min) this fixed dose combination should be administered with caution.
Međutim kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenu funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali < 60 ml/min).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but <60 ml/min) this fixed dose combination should be administered with caution.
Međutim, kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenu funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali < 60 ml/min).
However, in patients with mild to moderate renal impairment (GFR 30 to 89 mL/min/1.73 m2) or mild hepatic impairment (Child-Pugh Class A) concomitantly receiving strong CYP3A inhibitors, such as itraconazole, ketoconazole, ritonavir and clarithromycin, the recommended dose is 25 mg once daily with or without food (see section 4.2).
Ipak, kod bolesnika s blagim do umjerenim oštećenjem bubrega (GFR 30 do 89 ml/min/1,73 m2) ili blagim oštećenjem jetre (Child-Pugh stadij A) koji istodobno primaju snažne inhibitore CYP3A, poput itrakonazola, ketokonazola, ritonavira i klaritromicina, preporučena doza je 25 mg jedanput na dan s hranom ili bez nje (vidjeti 4.2).
However, in patients with severe renal impairment (creatinine clearance < 30 ml/min) or end-stage renal disease requiring haemodialysis or peritoneal dialysis, bedaquiline concentrations may be increased due to alteration of active substance absorption, distribution, and metabolism secondary to renal dysfunction.
Međutim, u bolesnika s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) ili završnim stadijem bubrežne bolesti koje zahtijeva hemodijalizu ili peritonealnu dijalizu, koncentracije bedakilina mogu biti povišene zbog izmjene apsorpcije djelatne tvari, distribucije i metabolizma kao posljedica bubrežne disfunkcije.
However, in phase I clinical trials, a limited number of patients were treated with daily doses of up to 1000 mg.
Međutim, u kliničkom ispitivanju faze I ograničen broj bolesnika liječen je dnevnim dozama do 1000 mg.
However, in Phase III trials in Parkinson’s disease patients no clinically meaningful influence of body weight on the therapeutic effect and tolerability of MIRAPEXIN prolonged-release tablets was detected.
Međutim, u fazi III kliničkog ispitivanja na bolesnicima s Parkinsonovom bolešću nije pronađen klinički značajan utjecaj tjelesne težine na terapijski učinak i podnošljivost MIRAPEXIN tableta s produljenim oslobađanjem.
However, in Phase III trials in Parkinson’s disease patients no clinically meaningful influence of body weight on the therapeutic effect and tolerability of pramipexole prolonged-release tablets was detected.
Međutim, u fazi III kliničkog ispitivanja na bolesnicima s Parkinsonovom bolešću nije pronađen klinički značajan utjecaj tjelesne težine na terapijski učinak i podnošljivost pramipeksol tableta s produljenim oslobađanjem.
However, in Phase III trials in Parkinson’s disease patients no clinically meaningful influence of body weight on the therapeutic effect and tolerability of SIFROL prolonged-release tablets was detected.
Međutim, u fazi III kliničkog ispitivanja na bolesnicima s Parkinsonovom bolešću nije pronađen klinički značajan utjecaj tjelesne težine na terapijski učinak i podnošljivost SIFROL tableta s produljenim oslobađanjem.
However, in post-marketing experience very rare cases of atrial flutter with 1:1 atrioventricular conduction are observed.
Međutim, nakon stavljanja lijeka u promet uočeni su vrlo rijetki slučajevi undulacije atrija s atrioventrikularnim provođenjem 1:1.
However, in rare cases severe local reactions that have required treatment and/or caused temporary incapacitation have been observed in patients who have used imiquimod according to the instructions.
Međutim, u rijetkim slučajevima zapažene su ozbiljne lokalne reakcije koje su zahtijevale liječenje, i/ili prouzročile poremećaj funkcije u bolesnika koji su se pridržavali uputa o primjeni kreme.
However, in repeat-dose toxicity studies in rats and dogs, no histopathological findings were noted on reproductive organs (see section 5.3).
Međutim, u ispitivanjima toksičnosti ponovljenih doza na štakorima i psima nisu opažene histopatološke promjene na reproduktivnim organima (vidjeti dio 5.3).
However, in repeated-dose toxicity studies performed in rats and monkeys, effects on female fertility were observed in the form of follicular atresia, degeneration of corpora lutea, endometrial changes in the uterus and decreased uterine and ovarian weights at clinically relevant systemic exposure levels.
Međutim, u istraživanjima toksičnosti ponovljenih doza na štakorima i majmunima, pri klinički značajnoj razini sustavne izloženosti lijeku, uočeni su učinci na plodnost ženki u obliku atrezije folikula, degeneracije žutih tijela, promjena endometrija uterusa te smanjenja težine uterusa i jajnika.
However, in safety laboratory trials, the use of COXEVAC in males proved to be safe.
Međutim, laboratorijska ispitivanja neškodljivosti korištenja vakcine COXEVAC u muških životinja potvrdila su njenu neškodljivost.
However, in safety laboratory trials, the use of the vaccine in males proved to be safe.
Međutim, laboratorijska ispitivanja neškodljivosti korištenja vakcine COXEVAC u muških životinja potvrdila su njenu neškodljivost.
However, in some cases the role of Aptivus cannot be excluded.
Međutim, u nekim slučajevima uloga Aptivusa se ne može isključiti.
However, in some cases these reactions have been severe, requiring treatment and/or causing incapacitation.
Međutim, u nekim su slučajevima te reakcije bile ozbiljne i zahtijevale su liječenje, odnosno prouzročile gubitak funkcije.
However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil fumarate discontinuation.
Međutim, u nekih se pacijenata zaraženih virusom HIV-1 smanjenje klirensa kreatinina nije potpuno riješilo usprkos prekidu terapije tenofovirdizoproksilfumarata.
However, in some patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil fumarate discontinuation.
Međutim, u nekih se pacijenata smanjenje klirensa kreatinina nije potpuno riješilo usprkos prekidu terapije tenofovirdizoproksilfumarata.
However, in some patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil fumarate discontinuation.
Međutim, u nekih se pacijenata smanjenje klirensa kreatinina nije potpuno riješilo usprkos prekidu terapije tenofovirdizoproksilfumaratom.
However, in study US301 no significant differences were observed between leflunomide and methotrexatein the primary efficacy parameters.
Međutim, u studiji US301 nisu zabilježene statistički značajne razlike između leflunomida i metotreksata u vrijednostima primarne djelotvornosti.
However, in the event that transient hypotension (low blood pressure) does occur, symptomatic treatment, e.g. fluid therapy, should be provided.
Međutim, u slučaju pojave prolazne hipotenzije potrebno je primijeniti simptomatsko liječenje, npr. terapiju tekućinom.
However, in the event that transient hypotension does occur, symptomatic treatment, e.g. fluid therapy, should be provided.
Međutim, u slučaju pojave prolazne hipotenzije, potrebno je primijeniti simptomatsko liječenje, npr. terapiju tekućinom.
However, in the main multiple myeloma and myelodysplastic syndromes registration trials where the efficacy and safety were established for lenalidomide, the medicinal product was administered without regard to food intake.
No, u glavnim ispitivanjima multiplog mijeloma i mijelodisplastičnih sindroma u svrhu registracije lijeka u kojima su utvrđene djelotvornost i sigurnost za lenalidomid, lijek je primjenjivan bez obzira na unos hrane.
However, in the pivotal multiple myeloma registration trials where the efficacy and safety were established for lenalidomide, the medicinal product was administered without regard to food intake.
No, u glavnim ispitivanjima multiplog mijeloma u svrhu registracije lijeka u kojima su utvrđene djelotvornost i sigurnost za lenalidomid, lijek je primjenjivan bez obzira na unos hrane.
However, in the pivotal multiple myeloma registration trials where the efficacy and safety were established for lenalidomide, the medicinal product was administered without regard to food intake.
No, u ključnim ispitivanjima multiplog mijeloma u svrhu registracije lijeka u kojima su utvrđene djelotvornost i sigurnost za lenalidomid, lijek je primjenjivan bez obzira na unos hrane.
However, in the subsequent 4 week randomised withdrawal phase of the study (Phase 2), the effect of aliskiren overlapped with the effects observed in patients switched to placebo in all dose groups (low, p=0.8894; mid, p=0.9511; high, p=0.0563).
Međutim, u kasnijoj 4-tjednoj randomiziranoj fazi ukidanja lijeka (ispitivanje faze 2), učinak aliskirena se podudarao s učincima uočenim u bolesnika prebačenih na placebo u svim doznim skupinama (niska, p=0,8894; srednja, p=0,9511; visoka, p=0,0563).
However, in the third study, patients with wild-type KRAS only survived overall for 16.3 months when Erbitux was added to the another oxaliplatin-based treatment similar to FOLFOX, compared with 18.2 months when the oxaliplatin-based treatment was used alone. the first study in patients who had taken chemotherapy before did not look at RAS mutations, but in the other two studies, patients with wild-type KRAS in their tumours lived for longer without their disease getting worse when Erbitux was added to their treatment.
No, u trećem ispitivanju, bolesnici samo s KRAS-om divljeg tipa živjeli su ukupno 16,3 mjeseci dulje nakon što je Erbitux dodan drugom liječenju temeljenom na oksaliplatinu koje je slično lijeku FOLFOX, u usporedbi s 18,2 mjeseca u slučaju liječenja kada je korišteno samo liječenje temeljeno na oksaliplatinu. prvo ispitivanje provedeno u bolesnika koji su primili kemoterapiju nije istražilo mutacije RAS-a.
However, in these cases the initially reconstituted solution of Voncento should not be diluted any further.
Međutim, u tim slučajevima prethodno pripremljena otopina lijeka Voncento se više ne smije razrjeđivati.
However, in these cases the initially reconstituted solution of Voncento should not be diluted any further.
Međutim, u tim slučajevima Voncento se više ne smije razrjeđivati.
However, in these patients, a starting dose higher than 100 micrograms may be considered.
Međutim, kod ovih bolesnika može se razmotriti primjena početne doze više od 100 mikrograma.
However, in this study no positive effects on PFS or OS were demonstrated in patients with KRAS wild-type tumours, either.
Međutim, u ovom ispitivanju nisu dokazani ni pozitivni učinci na PFS ili OS u bolesnika s tumorima tipa „divljeg tipa“ KRAS.
However, in those with an artificial lens in the affected eye or who previously have not responded to or are unsuitable for other non-corticosteroid treatments, the benefits of Ozurdex were considered to outweigh the risks.
Međutim, kod onih osoba s umjetnom lećom koje nisu reagirale na terapiju ili se na njih terapija nekortikosteroidima nije mogla primijeniti, kao ni druge terapije koje nisu uključivale kortikosteroide, smatrano je da koristi lijeka Ozurdex nadmašuju rizike.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
Međutim, s obzirom na moguće rizike povezane s teškom leukocitozom, određivanje broja bijelih krvnih stanica treba raditi u redovitim intervalima za vrijeme terapije filgrastimom.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
No sa stajališta mogućih rizika povezanih s jakom leukocitozom, pri terapiji filgrastimom potrebno je u redovitim vremenskim razmacima, provjeravati broj leukcita.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
No sa stajališta mogućih rizika povezanih s jakom leukocitozom, pri terapiji filgrastimom potrebno je u redovitim vremenskim razmacima, provjeravati broj leukocita.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
No sa stajališta mogućih rizika povezanih s teškom leukocitozom, pri liječenju filgrastimom valja redovito, u određenim vremenskim razmacima, provjeravati broj leukocita.
However, in vitro electrophysiological studies indicate that both eslicarbazepine acetate and its metabolites stabilise the inactivated state of voltage-gated sodium channels, preventing their return to the activated state and thereby sustaining repetitive neuronal firing.
Međutim, elektrofiziološke studije in vitro pokazuju da i eslikarbazepinacetat i njegovi metaboliti stabiliziraju inaktivirano stanje o naponu ovisnih natrijevih kanala, spriječavajući njihov povratak u aktivno stanje, a time suzdržavaju ponavljajuće okidanje neurona.
However, in vitro studies indicated that clinical drug-drug interactions are unlikely to occur as a result of crizotinib-mediated inhibition of the metabolism of drugs that are substrates for UGT1A4, UGT1A6, or UGT1A9.
Međutim, in vitro ispitivanja pokazala su da nisu vjerojatne kliničke interakcije s drugim lijekovima kao posljedica krizotinibom posredovane inhibicije metabolizma lijekova koji su supstrati za UGT1A4, UGT1A6, ili UGT1A9.
However, in-use stability has been demonstrated for 30 minutes when stored at 20C – 25C.
Međutim, dokazana stabilnost u primjeni je 30 minuta ako se čuva na temperaturi od 20°C–25°C.
However, individuals should be informed that dizziness has been reported during treatment with both emtricitabine and tenofovir disoproxil fumarate.
No osobe je potrebno obavijestiti da je zabilježena omaglica tijekom liječenja i emtricitabinom i tenofovirdizoproksilfumaratom.
However, infection with Mycoplasma hyopneumoniae was not eliminated.
Međutim, infekcija s Mycoplasma hyopneumoniae nije eliminirana.
However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.
Međutim može se razmotriti započinjanje terapije dozom od 75 mg, posebice u hemodijaliziranih bolesnika i u bolesnika starijih od 75 godina.
However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.
Međutim u hemodijaliziranih bolesnika i u bolesnika starijih od 75 godina može se razmotriti započinjanje terapije dozom od 75 mg.
However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.
Međutim, može se razmotriti započinjanje terapije dozom od 75 mg, posebice u hemodijaliziranih bolesnika i u bolesnika starijih od 75 godina.
However, interactions with, MATE1 and OCT2 substrates cannot be excluded.
Međutim, interakcije sa supstratima MATE1 i OCT2 ne mogu se isključiti.
However, interferon alfa-2b may cause sleepiness, tiredness or confusion.
Međutim, interferon alfa-2b može uzrokovati pospanost, umor ili smetenost .
However, interpretive breakpoints for caspofungin have not been approved by EUCAST.
Međutim, EUCAST nije odobrio interpretativne granične vrijednosti za kaspofungin.
However, intestinal folate absorption may be impaired during long-term treatment of BindRen.
Međutim, apsorpcija folata u crijevima može biti narušena tijekom dugotrajnog liječenja BindRenom.
However, investigator should be strongly requested to obtain a recent sample for determination of the RET status as often as possible, even in patients previously tested at an earlier stage of their disease.
Međutim, od ispitivača je potrebno odlučno zahtijevati da što je moguće češće pribavi svjež uzorak za određivanje statusa RET mutacije, čak i u bolesnika prethodno testiranih u ranijoj fazi bolesti.
However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Međutim, može se očekivati da će cijepljenje spriječiti hepatitis D (koji uzrokuje delta agens) jer se hepatitis D ne razvija ako ne postoji infekcija virusom hepatitisa B.
However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Međutim, može se očekivati da će imunizacija spriječiti i hepatitis D zato što se hepatitis D (prouzročen delta agensom) ne javlja ako nije prisutna i infekcija virusom hepatitisa B.
However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Međutim, može se očekivati da će imunizacija spriječiti i hepatitis D zato što se hepatitis D (prouzročen delta agensom) ne javlja ako nije prisutna i zaraza hepatitisom B.
However, it concluded that the medicine should only be considered for use as ‘last line’ therapy, when no other protease inhibitors are predicted to work.
No, zaključilo je da lijek treba smatrati „zadnjom linijom” terapije, u slučajevima kada drugi inhibitori proteaze ne djeluju.
However, it is advisable to wait and see how you feel after taking Filgrastim HEXAL and before driving or operating machinery.
No preporučuje se da pričekate kako biste vidjeli kako se osjećate nakon uzimanja lijeka Filgrastim HEXAL i prije upravljanja vozilom ili rada sa strojevima.
However, it is advisable to wait and see how you feel after taking Grastofil and before driving or operating machinery.
Ipak, prije upravljanja vozilima ili rukovanja strojevima preporučljivo je pričekati da vidite kako ćete se osjećati nakon uzimanja lijeka Grastofil.
However, it is advisable to wait and see how you feel after taking Nivestim and before driving or operating machinery.
Međutim, savjetuje se da pričekate i vidite kako se osjećate nakon uzimanja Nivestima te prije upravljanja vozilima i rada na strojevima.
However, it is advisable to wait and see how you feel after taking Zarzio and before driving or operating machinery.
No preporučuje se da pričekate kako biste vidjeli kako se osjećate nakon uzimanja lijeka Zarzio i prije upravljanja vozilom ili rada sa strojevima.
However, it is not currently certain to what extent topical treatment with Panretin gel would increase 9-cis-retinoic acid plasma concentrations, in women with KS above naturally occurring levels; therefore, alitretinoin should not be used in pregnant women.
Međutim, trenutno nije sigurno u kojoj bi mjeri topikalno liječenje Panretinom povećalo koncentracije 9-cis-retinoične kiseline iznad fizioloških razina u plazmi žena s KS; stoga se alitretinoin ne smije primjenjivati u trudnica.
However, it is not known if CHAMPIX actually increases alcohol intoxication.
Međutim, nije poznato da li CHAMPIX uistinu povećava intoksikaciju alkoholom.
However, it is not known whether telmisartan was the cause."
Međutim, nije poznato je li telmisartan bio uzrok.
However, it is not necessary to keep bitches away from treated dogs following subsequent implantations for the initial 8 week period, provided that the veterinary medicinal product is administered every 12 months.
Kuje ipak nije potrebno držati dalje od tretiranih pasa poslije ponovljenih implantacija u početnom periodu od 8 tjedana ukoliko se VMP daje svakih 12 mjeseci.
However, it is theoretically possible that a breast-fed baby could experience serious side effects to Betaferon.
No, teoretski je moguće da se u dojenčeta jave ozbiljne nuspojave na Betaferon.
However, it is theoretically possible that a breast-fed baby could experience serious side effects to Extavia.
Međutim, teoretski je moguće da bi dijete koje doji moglo osjetiti teške nuspojave Extavije.